MEDLATEC OncoSure Hereditary Cancer Risk Test

OncoSure is a hereditary cancer genetic risk assessment offered by MEDLATEC, designed to identify inherited genetic variants associated with increased susceptibility to certain cancers.

The test analyses a panel of 17 genes associated with 15 hereditary cancer conditions, providing a broader genetic risk assessment than smaller, cancer-specific panels.

Unlike tests designed to identify cancer-associated signals in blood, OncoSure evaluates inherited genetic susceptibility. It does not determine whether cancer is currently present.

What Does OncoSure Assess?

• Hereditary Cancer Susceptibility

OncoSure examines inherited genetic variants associated with certain hereditary cancer conditions.

• Multiple Hereditary Cancer Conditions

The panel covers 15 hereditary cancer conditions, allowing patients and healthcare professionals to explore a broader range of inherited cancer risks.

• Genetic Information Relevant to Family Members

Certain inherited variants may have implications for biological relatives. Genetic counselling can help determine whether additional family assessment is appropriate.

The exact genes, associated conditions and limitations of the panel should be reviewed using MEDLATEC's current test documentation.

Key Benefits of OncoSure

• Comprehensive Hereditary Cancer Risk Assessment

OncoSure evaluates 17 genes associated with 15 hereditary cancer conditions, offering a broader assessment than smaller genetic testing panels.

• Supports Personalised Preventive Healthcare

Genetic findings may help healthcare professionals recommend appropriate risk assessment, screening strategies and further medical consultation.

• Useful for Individuals with Family Cancer History

Patients with a personal or family history suggestive of hereditary cancer may benefit from discussing genetic testing with a qualified healthcare professional.

• Provides Insights for Family Health Planning

Some clinically significant inherited variants may also be relevant to biological relatives, supporting informed discussions about family genetic risk assessment.

• Generally a One-Time Genetic Assessment

Inherited genetic variants are generally stable throughout life, so routine annual repetition of the same germline genetic test is usually unnecessary. Additional testing may be appropriate when clinical circumstances or genetic knowledge change.

Who May Consider OncoSure?

OncoSure may be considered by individuals who:

• Have multiple biological relatives diagnosed with cancer.

• Have a family history of cancer diagnosed at a relatively young age.

• Have a personal history suggestive of a hereditary cancer syndrome.

• Have relatives with known pathogenic hereditary cancer variants.

• Have been advised to undergo hereditary cancer genetic testing.

• Want to discuss broader inherited cancer susceptibility with a healthcare professional.

The most appropriate genetic test depends on individual and family history. A broader panel is not necessarily the best choice for every patient.

Testing Process

1. Pre-Test Consultation: Review personal and family medical history, testing suitability and potential implications of genetic results.

2. Sample Collection: A biological sample is collected according to MEDLATEC's testing requirements.

3. Genetic Analysis: The laboratory analyses the selected 17-gene panel.

4. Results: Results are generally expected in approximately 15 working days, subject to laboratory confirmation.

5. Genetic Counselling and Follow-Up: A qualified healthcare professional interprets the findings and discusses appropriate next steps.

Understanding Your Results

• Pathogenic or Likely Pathogenic Variant

A clinically significant inherited variant may indicate increased susceptibility to certain cancers. It does not mean cancer is currently present or will definitely develop.

• No Reportable Pathogenic Variant Identified

A negative result does not eliminate hereditary or non-hereditary cancer risk. Other genetic factors, family history and environmental influences may still contribute to overall risk.

• Variant of Uncertain Significance (VUS)

Some genetic variants cannot currently be classified as harmful or harmless. Such findings generally should not independently determine medical management.

Key Data

• Test Name: OncoSure

• Test Category: Hereditary Cancer Genetic Risk Assessment

• Genetic Panel: 17 Genes

• Conditions Assessed: 15 Hereditary Cancer Conditions

• Purpose: Assessment of Inherited Cancer Susceptibility

• Expected Result Time: Approximately 15 Working Days

Your Healthcare Journey in Vietnam with MediHub

MediHub supports international patients travelling to Vietnam for healthcare services, including genetic testing and preventive healthcare planning.

Our support services may include:

• Healthcare service and genetic testing consultation

• Appointment scheduling with MEDLATEC

• Pre-arrival guidance and preparation

• Visa and travel assistance where required

• Airport transfers and local transportation

• Accommodation arrangements

• Medical interpreter coordination

• Assistance during medical appointments

• Medical results and follow-up coordination

• Travel and tourism arrangements during your stay

Plan Your Genetic Testing Journey in Vietnam

Interested in understanding your hereditary cancer risk?

Contact MediHub for personalised assistance in planning your genetic testing journey in Vietnam. Our team can help coordinate your OncoSure appointment with MEDLATEC, provide pre-arrival guidance and assist with travel and follow-up arrangements.

Important Medical Information

OncoSure is a hereditary genetic risk assessment, not a test for diagnosing cancer or detecting an existing tumour.

An increased genetic risk does not mean cancer will necessarily develop, and a negative result does not eliminate cancer risk.

Genetic testing results should be interpreted by appropriately qualified healthcare professionals, ideally with access to genetic counselling. Recommended cancer screening and clinical assessment may still be necessary regardless of the genetic test result.